José Angel Richter-rekin lankidetzan egindako argitalpenak (84)

2022

  1. Valor diagnóstico de la SPECT/TAC cuantitativa en la evaluación de la sacroilitis activa de pacientes con espondilartritis axial y/o dolor lumbar inflamatorio

    Anales del sistema sanitario de Navarra, Vol. 45, Núm. 1, pp. 8-8

2020

  1. Incidental diagnosis of neuroendocrine tumour with 68Ga-PSMA PET/CT: Report of clinical case

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 39, Núm. 2, pp. 102-103

2018

  1. Significant dose reduction is feasible in FDG PET/CT protocols without compromising diagnostic quality

    Physica Medica, Vol. 46, pp. 134-139

2017

  1. Effective dose estimation for oncological and neurological PET/CT procedures

    EJNMMI Research, Vol. 7, Núm. 1

2016

  1. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT

    Lung Cancer, Vol. 97, pp. 81-86

  2. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  3. Index lesion characterization by 11C-Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma

    Prostate, Vol. 76, Núm. 1, pp. 3-12

  4. Radiation dose produced by patients during radiopharmaceutical incorporation in nuclear medicine diagnostic procedures

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 35, Núm. 3, pp. 175-185

2015

  1. Brain PET imaging optimization with time of flight and point spread function modelling

    Physica Medica, Vol. 31, Núm. 8, pp. 948-955

  2. Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand [18F]-tetrafluoroborate

    EJNMMI Research, Vol. 5, Núm. 1, pp. 1-9

2014

  1. Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging

  2. PET optimization for improved assessment and accurate quantification of 90Y-microsphere biodistribution after radioembolization

    Medical Physics, Vol. 41, Núm. 9

  3. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Núm. 11, pp. 2058-2065

  4. Validación de técnicas de segmentación para la tomografía por emisión de positrones mediante imágenes ex-vivo de piezas quirúrgicas oncológicas

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 33, Núm. 2, pp. 79-86

  5. ¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation

    Revista española de medicina nuclear e imagen molecular, Vol. 33, Núm. 5, pp. 280-285

2013

  1. Aportación del tiempo de vuelo y de la modelización de la respuesta a una fuente puntual a las características de funcionamiento del tomógrafo PET/TAC Biograph mCT

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 32, Núm. 1, pp. 13-21

  2. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 40, Núm. 9, pp. 1394-1405

  3. Impact of time-of-flight and point-spread-function in SUV quantification for oncological PET

    Clinical Nuclear Medicine, Vol. 38, Núm. 2, pp. 103-109

  4. Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism

    International Journal of Cancer, Vol. 133, Núm. 9, pp. 2157-2164

2012

  1. La tomografía por emisión de positrones

    Medicina nuclear en la práctica clínica (Aula Médica Ediciones), pp. 295-308